Form 4: TScan Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Leiden Dworak, Vice President of Finance at TScan Therapeutics, was granted stock options to purchase 46,875 shares of common stock.
Summary
- On January 12, 2024, Leiden Dworak, Vice President of Finance at TScan Therapeutics, received stock options.
- These options allow Dworak to purchase 46,875 shares of TScan Therapeutics' voting common stock at an exercise price of $6 per share.
- The options vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date and the remaining balance vesting in equal monthly installments over the subsequent 36 months, contingent upon continuous service to the Issuer.
- The options expire on January 12, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event and generally viewed as a positive incentive for management.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
- Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
- The vesting schedule and exercise price are generally aligned with industry norms to incentivize long-term performance and retention.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the executive to drive company performance.
- Employees may see the grant as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/12/2024 | Date of the stock option grant. |
| 01/12/2025 | First vesting date for 25% of the stock options. |
| 01/12/2034 | Expiration date of the stock options. |
Keywords
stock options, TScan Therapeutics, Form 4, executive compensation, insider transaction, beneficial ownership, equity securities, TCRX, Dworak
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.